RXi Pharmaceuticals Profile

3.30
USD 0.18  5.17%
17%
12%

RXi Pharmaceuticals exotic insider transaction detected

RXi Pharmaceuticals Corporation insider trading alert for general transaction of common stock $0.0001 par value by Geert Cauwenbergh, President CEO, on October 2, 2017. This event was filed by Rxi Pharmaceuticals Corp with SEC on 2017-10-02. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

RXi Pharmaceuticals Summary

RXi Pharmaceuticals Corporation (RXII) is traded on Nasdaq Capital Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 15 people. RXi Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Nano-Cap' category with current market capitalization of 7.63 M. RXi Pharmaceuticals Corporation conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 2.37 M outstanding shares of which 1.76 M shares are at this time shorted by private and institutional investors with about 4.32 trading days to cover. RXI PHARMACEUTICA currently holds about 5.42 M in cash with (8.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.29.
Check RXi Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected RXi Pharmaceuticals Corporation Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

RXi Pharmaceuticals Against Markets

Current Ratings

RXi Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
< 94% 
Equity ratings for RXi Pharmaceuticals Corporation are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
RXi Pharmaceuticals Corporation, a clinical-stage company, focuses on developing therapeutics for unmet medical needs. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. RXi Pharmaceuticals operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets exchange. It employs 15 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameRXi Pharmaceuticals Corporation
President CEO, DirectorGeert CauwenberghAll Leadership
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
LocationMASSACHUSETTS, U.S.A
Business Address257 Simarano Drive
ExchangeNasdaq Capital Markets
CUSIP74979C303
SectorHealthcare
IndustryPharmaceutical Products
BenchmarkDOW
Websitewww.rxipharma.com
Contact Number508 767 3861
Related EntityRXIIW
CurrencyUSD - US Dollar

Recommendations

RXi Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
8.0Strong Buy1Odds
RXi Pharmaceuticals Corporation current and past analyst recommendations published by number of research institutions as well as average analyst consensus
RXi Pharmaceuticals Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Directors

RXi Pharmaceuticals Corporate Directors
Robert Bitterman Director, MBA
Keith Brownlie Director
Jonathan Freeman Independent Director, MBA